2023 World Conference on Lung Cancer (Posters)-P2.09. Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression

Pdf Summary

This study aimed to investigate the efficacy of high-dose aumolertinib rechallenge in patients with non-small cell lung cancer (NSCLC) who had developed resistance to aumolertinib. The researchers wanted to determine if increasing the dose of the original EGFR-TKI drug would benefit patients who experienced gradual progression after initial treatment. The study included NSCLC patients with gradual progression or central nervous system (CNS) progression who had been initially treated with aumolertinib 110 mg once daily.<br /><br />The results of the study showed that high-dose aumolertinib had extended effectiveness in treating EGFR-mutated NSCLC patients with gradual progression, even in cases with brain metastases. The higher dose was well tolerated and did not result in a significant increase in adverse events. The researchers concluded that increasing the dose of aumolertinib may be a viable approach in these patients.<br /><br />The study design included two cohorts: cohort 1 comprised patients who received aumolertinib as first-line treatment, and cohort 2 comprised patients who received it as second-line treatment. The primary endpoints of the study were progression-free survival (PFS2), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events.<br /><br />Baseline characteristics of the patients included age, gender, smoking history, and Eastern Cooperative Oncology Group performance status (ECOG PS). The study also assessed anti-tumor efficacy, including tumor response, ORR, DCR, median duration of treatment (mDOT), and PFS2 rates at 6 and 12 months.<br /><br />Until April 1, 2023, the median PFS2 had not been reached. The 6-month and 12-month PFS2 rates were 95% and 80% respectively. Most patients had a median duration of treatment of over 9.5 months, with the longest duration of treatment being 23 months. Adverse events related to the treatment were mainly rash and diarrhea, with the majority being mild.<br /><br />In conclusion, this study suggests that increasing the dose of aumolertinib may have extended effectiveness in treating patients with EGFR-mutated NSCLC who experience gradual progression. Further studies with more patients and longer follow-up periods are needed to validate these findings.

Asset Subtitle

Jun Li

Meta Tag

Speaker Jun Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

high-dose aumolertinib rechallenge

NSCLC

resistance to aumolertinib

gradual progression

brain metastases

progression-free survival

adverse events

anti-tumor efficacy

PFS2 rates

EGFR-mutated NSCLC